Rosnowska M, Cendrowski W, Sobczyk W
Zakładu Biochemii Instytutu Psychiatrii i Neurologii w Warszawie.
Pol Merkur Lekarski. 1997 Apr;2(10):254-5.
Leukotrienes B4 and C4 have been assayed in CSF of 24 patients with the attacks or slowing-progressing course of multiple sclerosis, and in 23 patients with other noninflammatory diseases. Leukotrienes concentrations have been assayed with RIA technique with the use of commercially available kits manufactured by Amersham. Leukotrienes B4 and C4 levels in CSF of patients with multiple sclerosis have been 91.8 +/- 5.6, and 88.6 +/- 7.5 pg, and have been significantly higher than those in other neurological disorders (p < 0.01). Mean LTB4 and LTC4 levels have been significantly lower in patients with atherosclerotic dementia (69, 12.2 and 63, 02.9 pg/ml) or in patients with headache (72.7 +/- 2.8 and 64.5 +/- 8.2 pg/ml). Higher LTB4 and LTC4 levels in patients with multiple sclerosis is probably due to both increased penetration through blood-brain barrier and their synthesis in blood-brain barrier, and cerebral nervous tissue. Further investigations are necessary to show whether LTB4 and LTC4 levels may indicate a stage of inflammatory process activity and enable to draw any conclusions on efficacy of anti-inflammatory therapy.
对24例患有发作性或进展缓慢型多发性硬化症的患者以及23例患有其他非炎性疾病的患者的脑脊液中的白三烯B4和C4进行了测定。使用Amersham公司生产的市售试剂盒,采用放射免疫分析技术测定白三烯浓度。多发性硬化症患者脑脊液中的白三烯B4和C4水平分别为91.8±5.6和88.6±7.5 pg,显著高于其他神经系统疾病患者(p<0.01)。动脉粥样硬化性痴呆患者(69、12.2和63、02.9 pg/ml)或头痛患者(72.7±2.8和64.5±8.2 pg/ml)的平均白三烯B4和白三烯C4水平显著较低。多发性硬化症患者较高的白三烯B4和白三烯C4水平可能是由于血脑屏障通透性增加以及它们在血脑屏障和脑神经组织中的合成增加所致。有必要进一步研究白三烯B4和白三烯C4水平是否可指示炎症过程活动的阶段,并能否就抗炎治疗的疗效得出任何结论。